The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Patients with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) often experience poor outcomes, and there is no established standard of care (SOC). Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, speaks on the Phase I/II JACKPOT8 study (NCT04105010), investigating golidocitinib, a JAK1 inhibitor, in the treatment of patients with R/R PTCL. Prof. Kim shares that patient response rates were encouraging and most adverse events were manageable. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
